Latest Insider Transactions at Karuna Therapeutics, Inc. (KRTX)
This section provides a real-time view of insider transactions for Karuna Therapeutics, Inc. (KRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Karuna Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Karuna Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2022
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,228
+22.16%
|
$71,596
$7.33 P/Share
|
|
Feb 15
2022
|
Laurie J Olson |
SELL
Open market or private sale
|
Direct |
1,000
-100.0%
|
$110,000
$110.0 P/Share
|
|
Feb 15
2022
|
Laurie J Olson |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+50.0%
|
$84,000
$84.86 P/Share
|
|
Feb 15
2022
|
Troy A. Ignelzi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,500
-5.67%
|
$166,500
$111.14 P/Share
|
|
Feb 15
2022
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+5.36%
|
$13,500
$9.2 P/Share
|
|
Feb 01
2022
|
Atul Pande |
SELL
Open market or private sale
|
Direct |
2,500
-100.0%
|
$275,000
$110.8 P/Share
|
|
Feb 01
2022
|
Atul Pande |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$40,000
$16.0 P/Share
|
|
Feb 01
2022
|
Stephen K. Brannan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,728
-43.59%
|
$850,080
$110.05 P/Share
|
|
Feb 01
2022
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,228
+25.18%
|
$61,368
$6.36 P/Share
|
|
Jan 03
2022
|
Atul Pande |
SELL
Open market or private sale
|
Direct |
2,500
-100.0%
|
$325,000
$130.44 P/Share
|
|
Jan 03
2022
|
Atul Pande |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$40,000
$16.0 P/Share
|
|
Jan 03
2022
|
Stephen K. Brannan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,728
-25.57%
|
$1,004,640
$130.79 P/Share
|
|
Jan 03
2022
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,228
+15.18%
|
$71,596
$7.33 P/Share
|
|
Dec 30
2021
|
Stephen K. Brannan Chief Medical Officer |
SELL
Bona fide gift
|
Direct |
15,000
-66.67%
|
-
|
|
Dec 21
2021
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,970
+11.98%
|
$62,730
$9.2 P/Share
|
|
Dec 01
2021
|
Stephen K. Brannan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,728
-27.87%
|
$981,456
$127.57 P/Share
|
|
Dec 01
2021
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,228
+16.45%
|
$61,368
$6.36 P/Share
|
|
Dec 01
2021
|
Atul Pande |
SELL
Open market or private sale
|
Direct |
2,500
-100.0%
|
$317,500
$127.73 P/Share
|
|
Dec 01
2021
|
Atul Pande |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$40,000
$16.0 P/Share
|
|
Nov 15
2021
|
Laurie J Olson |
SELL
Open market or private sale
|
Direct |
1,000
-100.0%
|
$138,000
$138.24 P/Share
|
|
Nov 15
2021
|
Laurie J Olson |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+50.0%
|
$84,000
$84.86 P/Share
|
|
Nov 08
2021
|
Troy A. Ignelzi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
13,500
-42.86%
|
$2,052,000
$152.32 P/Share
|
|
Nov 08
2021
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,500
+30.0%
|
$121,500
$9.2 P/Share
|
|
Nov 02
2021
|
Andrew Craig Miller President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
26,500
+32.79%
|
$53,000
$2.92 P/Share
|
|
Nov 01
2021
|
Atul Pande |
SELL
Open market or private sale
|
Direct |
2,500
-100.0%
|
$340,000
$136.67 P/Share
|
|
Nov 01
2021
|
Atul Pande |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$40,000
$16.0 P/Share
|
|
Nov 01
2021
|
Stephen K. Brannan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,728
-15.47%
|
$1,051,008
$136.67 P/Share
|
|
Nov 01
2021
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,228
+12.12%
|
$61,368
$6.06 P/Share
|
|
Nov 01
2021
|
Andrew Craig Miller President of R&D |
SELL
Open market or private sale
|
Direct |
2,827
-0.89%
|
$398,607
$141.29 P/Share
|
|
Oct 04
2021
|
Andrew Craig Miller President of R&D |
SELL
Open market or private sale
|
Direct |
3,029
-9.82%
|
$378,625
$125.17 P/Share
|
|
Oct 01
2021
|
Andrew Craig Miller President of R&D |
SELL
Open market or private sale
|
Direct |
13,471
-5.53%
|
$1,643,462
$122.08 P/Share
|
|
Oct 01
2021
|
Atul Pande |
SELL
Open market or private sale
|
Direct |
2,500
-100.0%
|
$300,000
$120.72 P/Share
|
|
Oct 01
2021
|
Atul Pande |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$40,000
$16.0 P/Share
|
|
Sep 10
2021
|
Troy A. Ignelzi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,900
-9.55%
|
$228,000
$120.05 P/Share
|
|
Sep 10
2021
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,900
+8.72%
|
$17,100
$9.2 P/Share
|
|
Sep 09
2021
|
Troy A. Ignelzi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
500
-2.7%
|
$60,000
$120.05 P/Share
|
|
Sep 09
2021
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+2.63%
|
$4,500
$9.2 P/Share
|
|
Sep 08
2021
|
Troy A. Ignelzi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,600
-15.61%
|
$896,800
$118.59 P/Share
|
|
Sep 08
2021
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,600
+12.5%
|
$68,400
$9.2 P/Share
|
|
Sep 02
2021
|
Andrew Craig Miller President of R&D |
SELL
Open market or private sale
|
Direct |
2,673
-5.69%
|
$334,125
$125.51 P/Share
|
|
Sep 01
2021
|
Andrew Craig Miller President of R&D |
SELL
Open market or private sale
|
Direct |
5,500
-3.59%
|
$649,000
$118.67 P/Share
|
|
Sep 01
2021
|
Atul Pande |
SELL
Open market or private sale
|
Direct |
2,500
-100.0%
|
$292,500
$117.82 P/Share
|
|
Sep 01
2021
|
Atul Pande |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$40,000
$16.0 P/Share
|
|
Aug 20
2021
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+21.74%
|
$45,000
$9.2 P/Share
|
|
Aug 18
2021
|
Steven M Paul |
BUY
Open market or private purchase
|
Indirect |
1,181
+1.07%
|
$125,186
$106.1 P/Share
|
|
Aug 17
2021
|
Steven M Paul |
BUY
Open market or private purchase
|
Indirect |
1,183
+1.09%
|
$124,215
$105.63 P/Share
|
|
Aug 16
2021
|
Andrew Craig Miller President of R&D |
SELL
Open market or private sale
|
Direct |
5,500
-3.22%
|
$572,000
$104.37 P/Share
|
|
Aug 16
2021
|
Andrew Craig Miller President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+17.73%
|
$25,000
$2.92 P/Share
|
|
Aug 02
2021
|
Atul Pande |
SELL
Open market or private sale
|
Direct |
2,500
-100.0%
|
$285,000
$114.17 P/Share
|
|
Aug 02
2021
|
Atul Pande |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$40,000
$16.0 P/Share
|